Lilly buys Loxo for $8bn cash
Eli Lilly & Co. will acquire Loxo Oncology Inc. (treatments for genomically-defined cancers) for $235 per share in cash (a 74% premium to Loxo’s market average in the ten days prior to the announcement), or approximately $8bn.
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com